IFIH1 and dermatomyositis: The cut-off level set in this study for anti-MDA5 Ab positivity (8.156) was lower than the kit manufacturer’s recommended cut-off level (32) for clinically amyopathic dermatomyositis developing into rapidly progressive ILD.